| Literature DB >> 19002172 |
M Kreuzer1, L Walsh, M Schnelzer, A Tschense, B Grosche.
Abstract
Data from the German miners' cohort study were analysed to investigate whether radon in ambient air causes cancers other than lung cancer. The cohort includes 58,987 men who were employed for at least 6 months from 1946 to 1989 at the former Wismut uranium mining company in Eastern Germany. A total of 20,684 deaths were observed in the follow-up period from 1960 to 2003. The death rates for 24 individual cancer sites were compared with the age and calendar year-specific national death rates. Internal Poisson regression was used to estimate the excess relative risk (ERR) per unit of cumulative exposure to radon in working level months (WLM). The number of deaths observed (O) for extrapulmonary cancers combined was close to that expected (E) from national rates (n=3340, O/E=1.02; 95% confidence interval (CI): 0.98-1.05). Statistically significant increases in mortality were recorded for cancers of the stomach (O/E=1.15; 95% CI: 1.06-1.25) and liver (O/E=1.26; 95% CI: 1.07-1.48), whereas significant decreases were found for cancers of the tongue, mouth, salivary gland and pharynx combined (O/E=0.80; 95% CI: 0.65-0.97) and those of the bladder (O/E=0.82; 95% CI: 0.70-0.95). A statistically significant relationship with cumulative radon exposure was observed for all extrapulmonary cancers (ERR/WLM=0.014%; 95% CI: 0.006-0.023%). Most sites showed positive exposure-response relationships, but these were insignificant or became insignificant after adjustment for potential confounders such as arsenic or dust exposure. The present data provide some evidence of increased risk of extrapulmonary cancers associated with radon, but chance and confounding cannot be ruled out.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19002172 PMCID: PMC2600695 DOI: 10.1038/sj.bjc.6604776
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Characteristics of the German uranium miners' cohort, 1960–2003
|
| |
|---|---|
| Duration of follow-up (years) | 35 (0.5–50) |
| Duration of employment (years) | 12 (0.5–40) |
| Duration of exposure (years) | 11 (1–44) |
| Age at first exposure (years) | 22 (14–67) |
| Cumulative exposure (WLM | 279 (>0–3224) |
|
| |
| External | |
| Cumulative exposure (mSv) | 48.6 (>0–908.6) |
| Long-lived radionuclides ( | |
| Cumulative exposure (kBqh m−3) | 4.2 (>0–132.2) |
| Arsenic ( | |
| Cumulative exposure (dust-years | 122.5 (>0–1417.4) |
| Fine dust ( | |
| Cumulative exposure (dust-years | 36.7 (>0–315.2) |
| Silica dust ( | |
| Cumulative exposure in (dust-years | 5.8 (>0–56.0) |
WLM=working level months.
Dust-year is defined as exposure to 1 μg m−3 for arsenic over 220 shifts each at 8 h.
Dust-year=1 dust-year is defined as exposure to 1 mg m−3 of fine dust or silica dust over 220 shifts each at 8 h.
Figure 1Mean annual exposure to radon and its progeny in working level months (WLM), external γ-radiation in mSv and long-lived radionuclides in kBqh m−3 among exposed miners.
Figure 2Mean annual cumulative exposure for exposed cohort members with respect to fine dust (n=56 914), silica dust (n=56 878) and arsenic exposure (n=17 554) in dust-years.
Number of deaths observed (O) and expected (E), ratio of observed to expected deaths (O/E), and 95% CI for selected cancer sites, 1960–2003
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Tongue, mouth, salivary gland and pharynx (C00–C14) | 99 | 105.0 | 131.8 | 0.80 | 0.65–0.97 |
| Oesophagus (C15) | 125 | 132.6 | 120.1 | 1.10 | 0.92–1.31 |
| Stomach (C16) | 588 | 623.7 | 542.2 | 1.15 | 1.06–1.25 |
| Colon (C17–C18) | 299 | 317.1 | 310.9 | 1.02 | 0.91–1.14 |
| Rectum (C19–C21) | 241 | 255.6 | 267.9 | 0.95 | 0.84–1.08 |
| Liver (C22) | 154 | 163.3 | 129.3 | 1.26 | 1.07–1.48 |
| Gallbladder (C23–C24) | 76 | 80.6 | 75.4 | 1.07 | 0.84–1.34 |
| Pancreas (C25) | 223 | 236.5 | 225.2 | 1.05 | 0.92–1.20 |
| Nose (C30–C31) | 8 | 8.5 | 8.0 | 1.06 | 0.46–2.09 |
| Larynx (C32) | 75 | 79.5 | 67.2 | 1.18 | 0.93–1.48 |
| Bone (C40–C41) | 13 | 13.8 | 21.4 | 0.64 | 0.34–1.10 |
| Malignant melanoma (C43) | 33 | 35.0 | 48.0 | 0.73 | 0.50–1.02 |
| Other skin (C44) | 9 | 9.5 | 12.5 | 0.76 | 0.35–1.45 |
| Connective tissue (C47 and C49) | 14 | 14.8 | 21.6 | 0.69 | 0.38–1.16 |
| Prostate (C61) | 262 | 277.9 | 314.4 | 0.88 | 0.78–1.00 |
| Testis (C62) | 25 | 26.5 | 25.3 | 1.05 | 0.68–1.55 |
| Kidney (C64–C66) | 162 | 171.8 | 161.6 | 1.06 | 0.91–1.24 |
| Bladder (C67–C68) | 173 | 183.5 | 224.4 | 0.82 | 0.70–0.95 |
| Brain and other nervous system (C70–C72) | 110 | 116.7 | 124.2 | 0.94 | 0.77–1.13 |
| Thyroid gland (C73) | 18 | 19.1 | 13.9 | 1.38 | 0.81–2.17 |
| Hodgkin's disease (C81) | 29 | 30.8 | 35.1 | 0.88 | 0.59–1.26 |
| Non-Hodgkin's disease (C82–C85 and C91.4) | 85 | 90.2 | 91.6 | 0.98 | 0.79–1.22 |
| Myeloma (C90) | 51 | 54.1 | 52.6 | 1.03 | 0.77–1.35 |
| Leukaemia (C91–C95, except C91.4) | 127 | 134.7 | 150.9 | 0.89 | 0.74–1.06 |
| Leukaemia excluding chronic lymphatic (C91–C95, except C91.1 and C91.4) | 71 | 75.3 | 83.9 | 0.90 | 0.70–1.13 |
| Other and unspecified | 295 | 312.8 | 312.5 | 1.00 | 0.89–1.12 |
| All cancers other than lung cancer (C00–C32 and C35–C97) | 3340 | 3543.7 | 3488.2 | 1.02 | 0.98–1.05 |
Exclusion of some cases for specific years, as external rates are missing (in total 46 missing cases).
O*, corrected for missing causes of death, O*=O/0.943; E=expected cases based on age and calendar year standardised national mortality rates from Eastern Germany.
Relative risk for selected cancer sites by cumulative radon exposure based on internal poisson regression, 1960–2003
|
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| ||
| Tongue and mouth | Cases | 3 | 12 | 5 | 11 | 1 | 6 | 0 | 38 | 0.045 | 0.50 |
| (C01–C06) | RR | 1.00 | 1.30 | 3.10 | 3.12 | 0.43 | 6.15 | — | |||
| Pharynx | Cases | 6 | 16 | 2 | 10 | 12 | 6 | 1 | 53 | 0.163 | 0.12 |
| (C09–C14) | RR | 1.00 | 0.97 | 0.54 | 1.27 | 2.85 | 3.33 | 1.18 | |||
| Oesophagus | Cases | 19 | 38 | 7 | 37 | 15 | 6 | 3 | 125 | −0.025 | 0.08 |
| (C15) | RR | 1.00 | 0.97 | 0.76 | 1.31 | 0.82 | 0.69 | 0.68 | |||
| Stomach | Cases | 76 | 143 | 35 | 141 | 95 | 62 | 38 | 590 | 0.021 | 0.04 |
| (C16) | RR | 1.00 | 1.21 | 1.42 | 1.34 | 1.16 | 1.51 | 1.77 | |||
| Colon | Cases | 51 | 74 | 13 | 66 | 41 | 44 | 10 | 299 | 0.017 | 0.26 |
| (C17–C18) | RR | 1.00 | 0.79 | 0.63 | 0.84 | 0.71 | 1.58 | 0.71 | |||
| Rectum | Cases | 39 | 55 | 16 | 53 | 39 | 22 | 17 | 241 | 0.028 | 0.13 |
| (C19–C21) | RR | 1.00 | 0.77 | 0.97 | 0.91 | 0.89 | 1.03 | 1.58 | |||
| Liver | Cases | 25 | 35 | 12 | 24 | 34 | 21 | 7 | 158 | 0.044 | 0.09 |
| (C22) | RR | 1.00 | 0.70 | 1.10 | 0.59 | 1.18 | 1.52 | 1.02 | |||
| Gallbladder | Cases | 15 | 17 | 3 | 19 | 12 | 9 | 6 | 81 | 0.021 | 0.46 |
| (C23–C24) | RR | 1.00 | 0.70 | 0.57 | 0.85 | 0.70 | 1.05 | 1.37 | |||
| Pancreas | Cases | 38 | 60 | 11 | 51 | 43 | 16 | 9 | 228 | −0.001 | >0.5 |
| (C25) | RR | 1.00 | 0.81 | 0.70 | 0.93 | 1.04 | 0.78 | 0.86 | |||
| Larynx | Cases | 13 | 15 | 2 | 16 | 20 | 8 | 1 | 75 | 0.021 | 0.49 |
| (C32) | RR | 1.00 | 0.66 | 0.40 | 0.92 | 1.51 | 1.23 | 0.29 | |||
| Prostate | Cases | 50 | 60 | 12 | 62 | 42 | 20 | 17 | 263 | 0.000 | >0.5 |
| (C61) | RR | 1.00 | 0.85 | 0.81 | 0.88 | 0.75 | 0.71 | 1.20 | |||
| Kidney | Cases | 26 | 44 | 12 | 42 | 23 | 13 | 11 | 171 | 0.017 | 0.39 |
| (C64–C66) | RR | 1.00 | 0.83 | 0.96 | 1.01 | 0.79 | 0.92 | 1.60 | |||
| Bladder | Cases | 22 | 34 | 10 | 42 | 39 | 22 | 8 | 177 | 0.020 | 0.28 |
| (C67–C68) | RR | 1.00 | 1.03 | 1.47 | 1.26 | 1.44 | 1.60 | 1.15 | |||
| Brain and others | Cases | 15 | 41 | 9 | 18 | 22 | 10 | 0 | 115 | −0.018 | 0.27 |
| (C70–C72) | RR | 1.00 | 1.32 | 1.33 | 0.85 | 1.56 | 1.52 | — | |||
| Non-Hodgkin's disease | Cases | 14 | 22 | 8 | 18 | 13 | 9 | 3 | 87 | 0.032 | 0.35 |
| (C82–C85 and C91.4) | RR | 1.00 | 0.71 | 1.34 | 1.00 | 1.05 | 1.54 | 1.05 | |||
| Myeloma | Cases | 13 | 11 | 2 | 14 | 7 | 7 | 1 | 55 | 0.007 | >0.5 |
| (C90) | RR | 1.00 | 0.40 | 0.37 | 0.82 | 0.56 | 1.22 | 0.34 | |||
| Leukaemia | Cases | 22 | 29 | 5 | 36 | 17 | 14 | 4 | 127 | 0.006 | >0.5 |
| (C91–C95, excluding C91.4) | RR | 1.00 | 0.75 | 0.57 | 1.13 | 0.75 | 1.26 | 0.71 | |||
| Other and unspecified | Cases | 75 | 137 | 24 | 93 | 74 | 31 | 23 | 457 | 0.009 | 0.44 |
| RR | 1.00 | 0.96 | 0.84 | 0.90 | 1.01 | 0.86 | 1.29 | ||||
| All non-lung cancers | Cases | 522 | 843 | 188 | 753 | 549 | 326 | 159 | 3340 | 0.014 | <0.001 |
| (C00–C32, C35–C97) | RR | 1.00 | 0.89 | 0.94 | 1.00 | 0.99 | 1.20 | 1.16 | |||
| Person-years at risk | 0-year lag | 256 264 | 781 696 | 102 726 | 290 243 | 191 867 | 92 371 | 47 019 | 1 762 208 | ||
| 5-year lag | 363 845 | 693 782 | 95 229 | 287 756 | 191 037 | 86 643 | 43 913 | 1 762 208 | |||
| Mean cumulative radon exposure | 0 | 11.1 | 71.9 | 263.4 | 732.1 | 1197.2 | 1940.8 | ||||
ERR/WLM=excess relative risk per working level months.
RR=relative risk.
Statistically significant (P<0.05).
Excess relative risk (ERR) per 100 WLM for specific cancer sites after accounting for various potential confounding factors, 1960–2003 – analyses restricted to individuals with available information on all considered confounders (n=56 278)
|
| ||||
|---|---|---|---|---|
|
|
|
|
|
|
| Without adjustment | 0.015 (0.006; 0.023) | 0.022 (0.001; 0.043) | 0.020 (−0.038; 0.078) | 0.042 (−0.009; 0.092) |
|
| ||||
| | 0.016 (0.007; 0.026) | 0.012 (−0.011; 0.035) | −0.009 (−0.067; 0.050) | 0.041 (−0.015; 0.098) |
| LRN | 0.016 (0.007; 0.026) | 0.011 (−0.013; 0.034) | −0.018 (−0.077; 0.014) | 0.047 (−0.009; 0.103) |
| Arsenic | 0.014 (0.005; 0.024) | 0.009 (−0.013; 0.031) | 0.009 (−0.053; 0.072) | NC |
| Fine dust | 0.011 (−0.0002; 0.023) | 0.007 (−0.022; 0.036) | −0.033 (−0.129; 0.063) | 0.022 (−0.045; 0.09) |
| Silica dust | 0.012 (−0.005; 0.024) | 0.012 (−0.018; 0.043) | −0.055 (−0.161; 0.050) | 0.034 (−0.035; 0.101) |
ERR/WLM=excess relative risk per working level months; NC=not calculable.
Risk of deaths from cancers other than lung cancer combined by cumulative radon exposure in WLM in the pooled 11 miner study and this study (categorical analyses and excess relative risk per WLM)
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| — | — | — | 0 | 363 845 | 522 | 1.00 | ||
| <50 | 295 078 | 405 | 0.98 | >0–50 | 693 782 | 843 | 0.89 | 0.79–0.99 |
| 50–99 | 87 286 | 183 | 1.04 | 50–99 | 95 229 | 188 | 0.94 | 0.77–1.10 |
| 100–499 | 222 305 | 515 | 0.99 | 100–499 | 287 756 | 753 | 1.00 | 0.88–1.12 |
| 500–999 | 42 231 | 93 | 1.02 | 500–999 | 191 037 | 549 | 0.99 | 0.86–1.11 |
| 1000–1499 | 10 686 | 25 | 1.11 | 1000–1499 | 86 643 | 326 | 1.20 | 1.02–1.37 |
| 1500+ | 12 108 | 32 | 1.10 | 1500+ | 43 913 | 159 | 1.16 | 0.94–1.76 |
| Total | 669 694 | 1253 | 1 762 208 | 3340 | ||||
| ERR/WLM | 0.01% (−0.01 to 0.02%) | 0.014% (0.006%–0.023%) | ||||||
Risk estimates based on comparisons with external mortality rates for the time period of more than 10 years since employment.
SMR=standardised mortality ratio, no confidence limits had been given in the original publication.
ERR/WLM=excess relative risk per working level months.
Figure 3Excess relative risk (ERR) per 100 WLM and 95% confidence limits for all cancer sites with >35 cases and all cancers other than lung cancer combined, 1960–2003.